Aligos Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
ALGS$3.95-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber · Exhibit Description · Incorporated by Reference · ProvidedHerewith | |||||
|---|---|---|---|---|---|
| Form · Date · Number | |||||
| 3.1(a) | Amended and Restated Certificate of Incorporation. | 8-K | 10/20/2020 | 3.1 | |
| 3.1(b) | Certificate of Amendment to Amended and Restated Certificate of Incorporation. | 8-K | 6/28/2024 | 3.1 | |
| 3.1(c) | Certificate of Amendment to Amended and Restated Certificate of Incorporation. | 8-K | 8/19/2024 | 3.1 | |
| 3.2 | Amended and Restated Bylaws. | 8-K | 10/20/2020 | 3.2 | |
| 4.1 | Reference is made to Exhibits 3.1(a), 3.1(b) and 3.2. | ||||
| 4.2 | Form of Common Stock Certificate. | 10-Q | 11/6/2024 | 4.2 | |
| 4.3 | Form of 2023 Common Warrant Agreement. | 8-K | 10/25/2023 | 4.2 | |
| 4.4 | Form of 2023 Pre-Funded Warrant Agreement. | 8-K | 10/25/2023 | 4.1 | |
| 4.5 | Form of 2025 Common Warrant Agreement | 8-K | 2/12/2025 | 4.2 | |
| 4.6 | Form of 2025 Pre-Funded Warrant Agreement | 8-K | 2/12/2025 | 4.1 | |
| 10.1# | Non-Employee Director Compensation Program | X | |||
| 10.2 | Securities Purchase Agreement, dated February 11, 2025, by and among the Company and the investors party thereto. | 8-K | 2/12/2025 | 10.1 | |
| 10.3 | Registration Rights Agreement, dated February 13, 2025, by and among the Company and the investors party thereto. | 10-K | 3/10/2025 | 10.18 | |
| 10.4 | Lead Investor Registration Rights Agreement, by and among the Company and the investors party thereto. | 10-K | 3/10/2025 | 10.19 | |
| 10.5 | Letter Agreement, by and among the Company and the investors party thereto. | 10-K | 3/10/2025 | 10.20 | |
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | Inline XBRL Instance Document. | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | |||
| 104 | The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 has been formatted in Inline XBRL. | X | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.